Hanxin Lu Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
faculty
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Hanxin Lu's research focuses on the development and preclinical evaluation of novel immunotherapies and the analysis of public health factors influencing disease outcomes. Lu has published work on VXX-401, a novel anti-PCSK9 vaccine candidate being investigated for the prevention of cardiovascular disease, demonstrating its ability to reduce LDL-C levels in non-human primates. Another area of investigation involves preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide (CGRP), relevant to conditions like migraine.
In addition to pharmaceutical research, Lu's work extends to public health, examining the impact of social determinants, lifestyle factors, and air pollution on allergic diseases and their comorbidities. This research utilizes multi-state analysis of prospective cohort data. Further public health interests include understanding preventive health care information-seeking behaviors, as evidenced by a study on Baby Boomers in Taiwan. Lu leads a research group and has a scholarly profile with an h-index of 20, 28 total publications, and 1,571 total citations. Key collaborators include Alexander N. Chen, Alexander Chen, Michael J. Rubach, and Mark E. McMurtrey, all affiliated with the University of Central Arkansas.
Metrics
- h-index: 20
- Publications: 29
- Citations: 1,576
Selected Publications
-
Preventive Health Care Information Seeking Behaviors among Baby Boomers in Taiwan (2025)
Collaboration Network
Top Collaborators
- VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
- Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide
- VXX-401, AN INVESTIGATIONAL PCSK9 VACCINE FOR THE PREVENTION OF CARDIOVASCULAR DISEASE
- VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
- Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide
- VXX-401, AN INVESTIGATIONAL PCSK9 VACCINE FOR THE PREVENTION OF CARDIOVASCULAR DISEASE
- VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
- Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide
- VXX-401, AN INVESTIGATIONAL PCSK9 VACCINE FOR THE PREVENTION OF CARDIOVASCULAR DISEASE
- VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
- Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide
- VXX-401, AN INVESTIGATIONAL PCSK9 VACCINE FOR THE PREVENTION OF CARDIOVASCULAR DISEASE
- VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
- Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide
- VXX-401, AN INVESTIGATIONAL PCSK9 VACCINE FOR THE PREVENTION OF CARDIOVASCULAR DISEASE
- VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
- Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide
- VXX-401, AN INVESTIGATIONAL PCSK9 VACCINE FOR THE PREVENTION OF CARDIOVASCULAR DISEASE
- VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
- VXX-401, AN INVESTIGATIONAL PCSK9 VACCINE FOR THE PREVENTION OF CARDIOVASCULAR DISEASE
- VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
- Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide
- VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
- Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide
- VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
- Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide
- VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
- Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide
- VXX-401, AN INVESTIGATIONAL PCSK9 VACCINE FOR THE PREVENTION OF CARDIOVASCULAR DISEASE
- VXX-401, AN INVESTIGATIONAL PCSK9 VACCINE FOR THE PREVENTION OF CARDIOVASCULAR DISEASE
- VXX-401, AN INVESTIGATIONAL PCSK9 VACCINE FOR THE PREVENTION OF CARDIOVASCULAR DISEASE
- VXX-401, AN INVESTIGATIONAL PCSK9 VACCINE FOR THE PREVENTION OF CARDIOVASCULAR DISEASE
Similar Researchers
Based on overlapping research topics